<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0282492" disease_type="Disease or Syndrome" abbrv="">Sneddon's syndrome</z:e> (SS) is an uncommon disorder, characterized by the association of <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> and widespread <z:hpo ids='HP_0000965'>livedo reticularis</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>The treatment options for SS to prevent <z:hpo ids='HP_0001297'>stroke</z:hpo> recurrence and future disability include antiplatelet therapy, anticoagulation, or immunosuppression </plain></SENT>
<SENT sid="2" pm="."><plain>We describe a patient with SS who presented with an <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo>, and was treated with intravenous recombinant tissue-plasminogen activator with significant neurologic improvement </plain></SENT>
<SENT sid="3" pm="."><plain>To our knowledge this is the first report of the use of thrombolysis in SS patients with <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>It suggests that thrombolytic therapy might be safe and effective in these patients </plain></SENT>
</text></document>